Skip to main content
OpenTrials
Completed

NCT Number: NCT04495218

NGS Panel of Incomplete Forms of Ocular Albinism

Implementation of a next-generation sequencing panel of genes to identify deleterious variants in patients with incomplete forms of albinism.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Scientific context : Albinism is clinically characterised by cutaneous hypopigmentation and ophthalmologic features. These features common to all forms of albinism are foveal hypoplasia, misrouting of the optic nerves at the chiasm, retinal hypopigmentation, translucent irides and nystagmus. The molecular genetic lab at Bordeaux University Hospital is the national reference for the study of this disease. More than 1400 patients have been analyzed with a strategy including next-generation sequencing of the 19 known genes of albinism and array-CGH. Despite this thorough analysis, 25% of patients remain without molecular diagnosis. Our experience tells us that these patients often show an incomplete form of albinism with the presence of only few ophthalmologic signs. The molecular diagnosis is very challenging as the phenotype often overlaps with other ophthalmologic disorders.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Minor and adult patient.
  • Patient presenting a clinical diagnosis of incomplete form of albinism with presence of at least 2 signs of ocular albinism among which nystagmus, low vision, foveal hypoplasia, retinal hypopigmentation, translucent irides, misrouting of the optic nerves at the chiasm.
  • Registered for the social security system.
  • Informed consent signed by patient or parent of a minor patient.

Exclusion criteria

  • Refusal to participate in research protocol.

Treatment and study plan

blood samples

Biological

Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.

Primary outcomes

  1. Percentage of patients for whom a molecular diagnosis is obtained based on the panel of targeted genes

    Time frame: Enrollment

    the prevalence of finding at least two pathogenic variants is 10%.

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Implementation of a Next-generation Sequencing Analysis of a Panel of Genes Implicated in Incomplete Forms of Albinism

Acronym: DIA

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Jul 31, 2020
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.